HomeInsightsStock Comparison

Alivus Life Sciences Ltd vs Shree Ganesh Remedies Ltd Stock Comparison

Alivus Life Sciences Ltd vs Shree Ganesh Remedies Ltd Stock Comparison

Last Updated on: Jun 03, 2025

Key Highlights

  • The Latest Trading Price of Alivus Life Sciences Ltd is ₹ 1060 as of 03 Jun 15:30.
  • The P/E Ratio of Alivus Life Sciences Ltd is 0 as of March 2020 .The P/E Ratio of Shree Ganesh Remedies Ltd is 6.2 as of March 2020.
  • The Market Cap of Alivus Life Sciences Ltd is ₹ 0 crore as of March 2020 .The Market Cap of Shree Ganesh Remedies Ltd is ₹ 65.04 crore as of March 2020.
  • The revenue of Alivus Life Sciences Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Shree Ganesh Remedies Ltd for the Mar '25 is ₹ 26.72 crore as compare to the Dec '24 revenue of ₹ 27.76 crore. This represent the decline of -3.75%.
  • The ebitda of Alivus Life Sciences Ltd for the Mar '25 is ₹ 0 crore as compare to the Dec '24 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Shree Ganesh Remedies Ltd for the Mar '25 is ₹ 12.16 crore as compare to the Dec '24 ebitda of ₹ 10.61 crore. This represent the growth of 14.61%.
  • The net profit of Alivus Life Sciences Ltd changed from ₹ 0 crore to ₹ 0 crore over 5 quarters. This represents a CAGR of 0.0% The net profit of Shree Ganesh Remedies Ltd changed from ₹ 12.59 crore to ₹ 6.59 crore over 5 quarters. This represents a CAGR of -40.42% .
  • The Dividend Payout of Alivus Life Sciences Ltd changed from 61.46 % on March 2022 to 58.56 % on March 2024 . This represents a CAGR of -1.60% over 3 yearsThe Dividend Payout of Shree Ganesh Remedies Ltd changed from 13.99 % on March 2020 to 2.28 % on March 2024 . This represents a CAGR of -30.43% over 5 years.

Share Price

* All values are in Rupees

PE

Market Cap

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Alivus Life Sciences Ltd

  • Glenmark Life Sciences Limited was incorporated as Zorg Laboratories Private Limited', on June 23, 2011 at Pune and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra at Pune.
  • Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' dated 10 August 2018.
  • A shareholders' resolution was passed on 13 August 2018 to convert the Company from a Private Limited Company to a Public Limited Company and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The Company is a wholly owned Subsidiary of Glenmark Pharmaceuticals Limited.
  • The Company acquired API Division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January, 2019.

About Shree Ganesh Remedies Ltd

  • Shree Ganesh Remedies Limited was originally incorporated as a Private Limited Company with the name 'Shree Ganesh Remedies Private Limited' at Ahmedabad, Gujarat on April 27, 1995.
  • Subsequently the Company was converted into a Public Limited and the name of the Company was changed to 'Shree Ganesh Remedies Limited' on July 28, 2017.
  • The Company, a part of Ganesh Group has carved for itself a niche in the industry of manufacturing pharmaceutical intermediates and fine chemicals. Shree Ganesh Remedies is a ISO 9001:2015, ISO 14001:2015 BS and OHSAS 18001:2007 certified Company and is engaged in manufacturing and dispatch of drug intermediates and chemicals like amine hydrochloride and specialty fine chemicals for pharmaceutical industry.
  • The Company manufactures products relating to antipsychotic, antiseptic, deprotonation reactions, hyperlipidemia, alzheimers and anti-viral.

Alivus Life Sciences Ltd News Hub

News

Board of Alivus Life Sciences recommends final dividend

Alivus Life Sciences announced that the Board of Directors of the Company at its meeting h...

Read more

16 May 2025 09:27

News

Alivus Life Sciences to hold board meeting

Alivus Life Sciences will hold a meeting of the Board of Directors of the Company on 15 Ma...

Read more

09 May 2025 10:57

News

Alivus Life Sciences allots 92,096 equity shares under ESOS

Alivus Life Sciences has allotted 92,096 equity shares under ESOS on 30 April 2025. Conseq...

Read more

30 Apr 2025 19:38

News

Alivus Life jumps after Q3 PAT climbs 15% YoY to Rs 137 cr

Profit before tax (PBT) climbed 15.22% YoY to Rs 185.14 crore in Q3 FY25. For Q3FY25, EBIT...

Read more

23 Jan 2025 15:01

News

Alivus Life Sciences Ltd leads gainers in 'A' group

Avantel Ltd, Sunteck Realty Ltd, Spandana Sphoorty Financial Ltd and Jai Corp Ltd are amon...

Read more

21 Jan 2025 12:00

News

Glenmark Life Sciences renamed as Alivus Life Sciences

Glenmark Life Sciences announced its change of identity to Alivus Life Sciences, marking a...

Read more

20 Jan 2025 10:18

Shree Ganesh Remedies Ltd News Hub

News

Shree Ganesh Remedies schedules board meeting

Shree Ganesh Remedies will hold a meeting of the Board of Directors of the Company on 19 M...

Read more

12 May 2025 10:22

News

Shree Ganesh Remedies to table results

Shree Ganesh Remedies will hold a meeting of the Board of Directors of the Company on 5 Fe...

Read more

30 Jan 2025 11:37

News

Shree Ganesh Remedies to declare Quarterly Result

Shree Ganesh Remedies will hold a meeting of the Board of Directors of the Company on 29 O...

Read more

24 Oct 2024 13:40

News

Shree Ganesh Remedies AGM scheduled

Shree Ganesh Remedies announced that the 29th Annual General Meeting (AGM) of the company ...

Read more

30 Sep 2024 10:05

News

Shree Ganesh Remedies announces board meeting date

Shree Ganesh Remedies will hold a meeting of the Board of Directors of the Company on 28 S...

Read more

21 Sep 2024 10:01

News

Shree Ganesh Remedies announces board meeting date

Shree Ganesh Remedies will hold a meeting of the Board of Directors of the Company on 12 A...

Read more

08 Aug 2024 16:04

SWOT Analysis Of Alivus Life Sciences Ltd

Strength

2

S

Weakness

2

W

Opportunity

1

O

Threats

0

T

SWOT Analysis Of Shree Ganesh Remedies Ltd

Strength

4

S

Weakness

1

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Alivus Life Sciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Shree Ganesh Remedies Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Alivus Life Sciences Ltd and Shree Ganesh Remedies Ltd

Which company has a larger market capitalization, Alivus Life Sciences Ltd or Shree Ganesh Remedies Ltd?

Market cap of Alivus Life Sciences Ltd is 12,711 Cr while Market cap of Shree Ganesh Remedies Ltd is 781 Cr

What are the key factors driving the stock performance of Alivus Life Sciences Ltd and Shree Ganesh Remedies Ltd?

The stock performance of Alivus Life Sciences Ltd and Shree Ganesh Remedies Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alivus Life Sciences Ltd and Shree Ganesh Remedies Ltd?

As of June 3, 2025, the Alivus Life Sciences Ltd stock price is INR ₹1036.55. On the other hand, Shree Ganesh Remedies Ltd stock price is INR ₹608.95.

How do dividend payouts of Alivus Life Sciences Ltd and Shree Ganesh Remedies Ltd compare?

To compare the dividend payouts of Alivus Life Sciences Ltd and Shree Ganesh Remedies Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions